Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer.

Nicoletto, M O; Padrini, R; Ferrazzi, E; Nascimben, O; Visonà, E; Tumolo, S; Palumbo, M; Costa, L; Vinante, O; Monfardini, S

Nicoletto, M O; Padrini, R; Ferrazzi, E; Nascimben, O; Visonà, E; Tumolo, S; Palumbo, M; Costa, L; Vinante, O; Monfardini, S.

Affiliation

Nicoletto MO; Medical Oncology Division, Padova General Hospital, Italy.

Eur J Cancer ; 29A(9): 1242-8, 1993.

Article in En | MEDLINE | ID: mdl-8343261

Subject(s)

Mitoxantrone/administration & dosage; Ovarian Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Female; Humans; Infusions, Parenteral; Middle Aged; Mitoxantrone/adverse effects; Mitoxantrone/pharmacokinetics; Ovarian Neoplasms/metabolism; Ovarian Neoplasms/mortality

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Mitoxantrone Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 1993 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links